Profile data is unavailable for this security.
About the company
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
- Revenue in EUR (TTM)14.93m
- Net income in EUR-1.37m
- Incorporated2007
- Employees168.00
- LocationPangaea Oncology SAQuiron Dexeus University HospitalC/ Sabino Arana, 5-19BARCELONA 08028SpainESP
- Phone+34 934097981
- Fax+34 935460172
- Websitehttps://www.panoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sequana Medical NV | 0.00 | -51.85m | 43.97m | 48.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -0.6848 | 0.00 | 1.61 | -- | 0.00 | -408.93 | -201.76 | -- | -- | -- | -427.70 | -- | -4,902.24 | 0.1559 | -0.5006 | 18.59 | -- | -85.19 | -35.84 | -37.13 | -- | -22.17 | -- |
| Anatolia TaniveBytklj Unli Ar Ge SiveTiA | 12.10m | -5.86m | 48.20m | 247.00 | -- | 1.49 | -- | 3.98 | -1.38 | -1.38 | 2.85 | 7.63 | 0.3282 | 0.7324 | 4.92 | 2,815,434.00 | -15.90 | 5.77 | -17.08 | 6.10 | 63.69 | 80.17 | -48.44 | 15.31 | 2.09 | -- | 0.0869 | -- | 54.06 | 91.00 | -10.92 | -- | 96.35 | -- |
| Herantis Pharma Oyj | 0.00 | -5.45m | 50.60m | 13.00 | -- | 28.93 | -- | -- | -0.2417 | -0.2417 | 0.00 | 0.0726 | 0.00 | -- | -- | 0.00 | -124.50 | -81.63 | -166.61 | -107.95 | -- | -- | -- | -- | -- | -17.91 | 0.6101 | -- | -- | -- | -1,865.03 | -- | -- | -- |
| hVIVO PLC | 58.81m | 6.06m | 55.95m | 301.00 | 9.23 | 1.12 | 5.45 | 0.9512 | 0.0077 | 0.0077 | 0.0748 | 0.0635 | 0.5914 | -- | 3.32 | 170,362.10 | 6.09 | 5.51 | 9.53 | 10.35 | -- | -- | 10.30 | 6.73 | 1.53 | -- | 0.2521 | 66.99 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Pangaea Oncology SA | 14.93m | -1.37m | 56.78m | 168.00 | -- | 2.77 | 40.91 | 3.80 | -0.0411 | -0.0382 | 0.4148 | 0.5955 | 0.5291 | 8.19 | 2.40 | 90,489.63 | -4.59 | -8.46 | -6.16 | -10.68 | 65.21 | 65.18 | -8.67 | -29.07 | 1.64 | -- | 0.1539 | -- | 93.14 | 33.89 | 68.36 | -- | 250.70 | -- |
| Skinbiotherapeutics PLC | 5.32m | -798.56k | 58.65m | 41.00 | -- | 5.43 | -- | 11.02 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Lytix Biopharma AS | 33.28k | -6.46m | 64.94m | 6.00 | -- | 8.16 | -- | 1,951.18 | -1.08 | -1.08 | 0.0055 | 1.15 | 0.005 | -- | 0.0579 | 62,833.33 | -96.51 | -61.17 | -123.25 | -71.49 | -- | -- | -19,422.02 | -722.29 | -- | -- | 0.0301 | -- | 178.98 | 104.67 | -7.24 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -8.96m | 65.96m | 16.00 | -- | -- | -- | -- | -2.21 | -2.21 | 0.00 | -0.1089 | 0.00 | -- | -- | 0.00 | -169.60 | -87.04 | -210.76 | -102.48 | -- | -- | -- | -- | -- | -2.14 | 1.33 | -- | -- | -- | 16.01 | -- | 2.20 | -- |
| Hamlet BioPharma AB | 0.00 | -5.35m | 66.05m | 6.00 | -- | 17.32 | -- | -- | -0.3157 | -0.3157 | 0.00 | 0.2927 | 0.00 | -- | -- | 0.00 | -95.68 | -78.53 | -104.48 | -91.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.70 | -- | -- | -- |
| Nanoform Finland Oyj | 2.96m | -21.77m | 67.25m | 173.00 | -- | 1.51 | -- | 22.75 | -0.2613 | -0.2613 | 0.0354 | 0.5203 | 0.0442 | 80.07 | 9.22 | 16,328.73 | -32.55 | -26.72 | -36.27 | -29.06 | -441.87 | -539.46 | -736.69 | -918.61 | 4.30 | -- | 0.1281 | -- | 8.22 | 124.15 | -12.87 | -- | -1.62 | -- |
| Oncopeptides AB | 5.92m | -25.34m | 69.22m | 75.00 | -- | 111.77 | -- | 11.69 | -1.20 | -1.20 | 0.2798 | 0.0253 | 0.2359 | 0.2049 | 1.79 | 782,225.00 | -100.98 | -148.24 | -125.09 | -215.27 | 97.88 | -- | -428.01 | -2,013.60 | 3.27 | -12.10 | 0.9507 | -- | -10.14 | -- | -14.25 | -- | -7.14 | -- |
Data as of Feb 03 2026. Currency figures normalised to Pangaea Oncology SA's reporting currency: Euro EUR
1.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Santander Private Banking Gestion SA SGIICas of 30 Jun 2025 | 425.54k | 1.24% |
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
